Peptides are short chains of amino acids linked by peptide (amide) bonds. They differ from proteins in size as proteins are much larger biomolecules composed of one or more chains of amino acids. Peptide therapeutics work by mimicking naturally occurring regulatory peptides or antagonist peptides that block receptors. Some key advantages of peptides as potential therapeutics include high target selectivity and fewer side effects compared to small molecule drugs.
Role in Treating Diabetes
Diabetes is one of the most common Peptide Therapeutics In Metabolic Disorders with rising prevalence globally. Both type 1 and type 2 diabetes result from insufficient insulin production or insulin resistance respectively. Several peptide therapeutics are being studied and developed for better glycemic control and diabetes management. Exenatide (Byetta) is the first FDA approved glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes treatment. GLP-1 is an incretin hormone secreted after meals that stimulates insulin secretion. Exenatide mimics the effects of endogenous GLP-1 to lower blood glucose levels.
Other GLP-1 receptor agonists liraglutide (Victoza) and lixisenatide (Adlyxin) have also been approved. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Pramlintide (Symlin) is an amylin mimetic used along with mealtime insulin injections to help control postprandial blood glucose in type 1 and type 2 diabetics. It suppresses glucagon secretion and slows gastric emptying to complement insulin action.
Other Peptide Applications
Several novel peptide therapies are being studied for metabolic syndrome, obesity, and related comorbidities. Mélanocortine-4 receptor (MC4R) agonists mimic the effects of alpha-melanocyte-stimulating hormone (α-MSH) to increase energy expenditure and reduce appetite. Setmelanotide is an MC4R agonist approved to treat rare genetic disorders resulting in extreme obesity. Additional MC4R agonists may help treat common obesity in future.
The appetite-regulating hormones peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) have potential applications in weight management. PYY3–36, which mimics fullness signal PYY, is being tested for obesity treatment. Co-administration of PYY with GLP-1 agonists could yield improved efficacy against obesity. Lipid-modifying agents are also emerging. Angiopoietin-like peptides (ANGPTL) 3, 4 and 8 regulate lipoprotein lipase (LPL) activity and inhibition shows promise for treating hypertriglyceridemia and fatty liver disease. Evinacumab, a fully human ANGPTL3 antibody, significantly lowered triglyceride levels in phase 2 studies. Eli Lilly has another ANGPTL3 antibody DSLD-8 in clinical trials.
Expanding Role in Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD refers to a spectrum of conditions caused by excessive fat accumulation in the liver. It ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and may progress to cirrhosis. Currently, no approved treatments exist for NASH, a leading cause of liver transplants. Several investigational peptides target metabolic derangements in NAFLD/NASH. Liraglutide (Victoza) and semaglutide, both GLP-1 receptor agonists approved for diabetes, reduced liver fat content and improved metabolic parameters in NAFLD/NASH patients during phase 2 trials.
Their anti-inflammatory and anti-fibrotic properties mediate relevant biological effects. Cendakimab, a PYY analogue, is in phase 2 trials for NASH. It reduces appetite, improves glycemic control, and promotes weight loss in diabetics. Angiopoietin-like peptides also impact NAFLD progression. Evinacumab's lipid-lowering ability led to major reductions in liver fat and fibrosis markers in a NASH trial.
ARHLP (Hepatic lipids) -8, an ANGPTL3 inhibitor from Akero Therapeutics, significantly decreased liver fat content and improved inflammation in a rodent NASH model. Clinical trials assessing various peptides offer hope that some may translate into the first approved medical therapies for NAFLD/NASH in the coming years. Their favorable safety profiles relative to small molecules also support use as backbone therapies in combination approaches.
Get More Insights on Peptide Therapeutics In Metabolic Disorders
Get this Report in Japanese Language-代謝疾患におけるペプチド治療薬
Get this Report in Korean Language- 대사 장애의 펩타이드 치료제
Also Read Related Healthcare Industry Blogs- Point-of-Care Blood Gas Analyzers: Revolutionizing On-Site Diagnostics
About Author-
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Known for her strong SEO background, she skillfully blends SEO strategies with insightful content. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
The global peptide based metabolic disorders therapeutics market is anticipated to show a value more than US$ 8 Bn and expected to grow at a robust rate during the period of forecast.Request for the Report Summary: https://www.factmr.com/report/187/peptide-based-metabolic-disorders-therapeutics-marketOngoing research and development activities have maintained their focus on treatments for human ailments.
The global peptide based metabolic disorders therapeutics market is positively impacted by factors such as efficacy, safety, innovations in drug discovery, easy synchronization, stability, etc.
The increase in the metabolic disorder rate has made it imperative to develop new treatments with peptides and this has spurred the adoption of peptide therapeutics in the treatment of metabolic disorders, thereby contributing to the growth of the global peptide based metabolic disorders therapeutics market.North America expected to grow at the highest CAGR to reflect a growth rate of 10.6% during the period of forecast as well as dominate the global market in terms of market share by revenue, as of 2017.
It can be said that this trend would be followed, considering the technological developments, and the higher investments in the healthcare industry that this segment portrays, and retain its dominant position by the end of 2022.Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S_id=187Asia-Pacific excluding Japan (APEJ) region also anticipated to grow at a similar growth rate as of North America region, yet does not portray high market share by revenue.
The market share by revenue of APEJ is less than one third than that of North America region and less than half of the market revenue share of the Europe region.Liraglutide segment by drug class is expected to grow at a robust rate during the period of forecast and dominates the market by drug class in terms of market share by revenue as of 2017.
These include companies like Bachem Holding AG, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, and CordenPharma International.Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM_id=187About UsFact.MR’s methodology is robust and comprehensive.
The Business Research Company published its Metabolic Disorders Drugs Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs market.
The report covers the metabolic disorders drugs market’s segments- anti diabetics drugs, anti-thyroid drugs, and others (hyperparathyroidism, hypopituitarism, hypoadrenalism).View Complete Report: https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-reportMetabolic Disorders Drugs Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region as well as by country.
It covers all the regions, key developed countries and major emerging markets.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.The FDA has approved various enzyme replacement therapies for the treatment of metabolic disorders.
Enzyme replacement therapy is used for treatment of rare genetic disorders through purified human, animal, or recombinant enzymes.
